Carole A. Sable


Carole is a clinical development expert with many years’ experience in the biotech and pharmaceutical industries. Most recently, she was CMO at Vitae Pharmaceuticals, Inc. prior to the acquisition by Allergan Plc.  Earlier she held the position of CMO at Revolution Medicines Plc. and prior to this was CMO at Scynexis, where she designed the development program for the antifungal SCY-078. Prior to this, Carole held various leadership positions across the infectious diseases and neuroscience therapeutic areas for Merck & Co. At Merck she oversaw NDA preparation for Suvorexant (BELSOMRA), and led the development of the antifungal caspofungin through its approval for multiple indications. Before Merck, Carole was CMO for Novexel SA (France), and President of Novexel, Inc. (USA), a biotech company specializing in the discovery and development of antibiotics. At Novexel, Carole designed and managed the development program for ceftazidime-avibactam through successful Phase 2B trials, the design of the first resistant pathogen study, and the acquisition of the company by Astra Zeneca.  Carole is an Infectious Diseases specialist trained at the University of Virginia and earned a Doctor of Medicine from Jefferson Medical College.